LENZ Therapeutics, Inc.
Nasdaq · Biological Products, (No Diagnostic Substances)
Company Overview
A concise company profile alongside the latest public filing activity.
LENZ Therapeutics is a biopharmaceutical company developing LNZ100, an eyedrop treatment using aceclidine to treat presbyopia, the age-related loss of near vision.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P.10% Owner | Sell | $7.26M | 2,159,516at $3.36 | Oct 29, 2026 |
| RA CAPITAL MANAGEMENT, L.P.10% Owner | Sell | $1.52M | 451,998at $3.36 | Oct 29, 2026 |
| RA CAPITAL MANAGEMENT, L.P.10% Owner | Sell | $360K | 107,170at $3.36 | Oct 29, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable LENZ activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.